<?xml version="1.0" encoding="UTF-8"?>
<p>The ProCID study is a prospective, randomised, double‐blind, parallel‐group, multi‐centre, phase III trial. An overview of the study design is shown in Figure 
 <xref rid="jns12267-fig-0001" ref-type="fig">1</xref>. The trial started in May 2017 and is expected to be completed by the end of 2019, corresponding to a total study duration of 30 months. The study will be conducted according to the ethical principles of the Declaration of Helsinki, and in compliance with the study protocol, International Conference on Harmonisation‐Good Clinical Practice E6 regulations, and applicable regulatory requirements. Trial registration: EudraCT 2015‐005443‐14; NCT02638207.
</p>
